PMI
10.10.2019 10:47:10 CEST | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced its aim that all its factories become carbon neutral by 2030. The announcement comes as PMI celebrates its factory in Klaipeda, Lithuania, as its first carbon neutral manufacturing facility.
“A clear message emerged from last month’s Climate Week NYC, run in coordination with the UN General Assembly: Now is the time to act against climate change,” said Huub Savelkouls, PMI’s Chief Sustainability Officer. “We share the ambition of limiting global temperature rise to 1.5 degrees Celsius. This requires setting challenging targets, taking action to achieve them and transparently reporting on progress and gaps. This is what our employees, our consumers and our shareholders expect from us. Today is important for PMI, as we celebrate our first step toward carbon neutrality in all our factories by 2030.”
At its factory in Klaipeda, Lithuania, PMI has implemented multiple projects over the past 10 years to optimize its energy usage and reduce carbon emissions. This has included upgrading utilities equipment, such as chillers and compressors, and facilitating heat recovery to optimize fuel use for heating purposes; installing a biomass boiler; procuring certified renewable electricity and offsetting natural gas carbon emissions with biogas certificates. To offset the remaining carbon emissions, PMI invested in Gold Standard certificates from climate protection initiatives. These initiatives support more than 9,000 families in India by promoting domestic biogas production to replace kerosene and firewood as cooking fuels, contributing to a reduction in greenhouse gas emissions and deforestation.
“Reducing the environmental footprint of our operations is a priority for PMI,” said Massimo Andolina, PMI’s Senior Vice President Operations. “I am extremely proud of our first important milestone in Klaipeda, testament to our commitment to make all PMI manufacturing operations carbon neutral by 2030. We are focused on, committed to and motivated by this objective, and we will achieve it thanks to the passion of all our people, to the ongoing efforts to reduce our energy needs and conserve energy inside our factories, and also thanks to a number of focused investments aimed at making all our operations environmentally sound and sustainable for the future.”
PMI is also actively pursuing initiatives to address the pressing climate challenge beyond its operations. For example, it is working with farmers and suppliers across its tobacco supply chain to lower the greenhouse gas emissions in the tobacco curing process by 70 percent by 2020 (vs. 2010) and to achieve zero net deforestation of natural forest by 2025.
In 2019—for the fifth consecutive year—PMI achieved the top score (Climate A-List) from CDP, the global disclosure system that enables organizations to measure and manage greenhouse gas emissions and other impacts. As one of its environmental commitments, PMI has set and committed to science-based targets—greenhouse gas emissions levels that science acknowledges as tolerable for the planet—and to go beyond these in its operations by aiming for carbon neutrality by 2030.
About Sustainability at PMI
For Philip Morris International (PMI), sustainability is about replacing cigarettes with better alternatives, addressing sustainability challenges across its value chain and seizing opportunities to add value to society. It is an integral part of the company’s business strategy. PMI takes decisive actions in areas where its work can have the greatest impact, from the more than 350,000 farmers from which it sources tobacco right up to the approximately 150 million consumers of PMI products. To learn more, visit www.pmi.com/sustainability .
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2019, PMI estimates that approximately 8.0 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 48 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005316/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
